When will generic GLP-1 medications be available?

Generic availability depends on patent expirations and ongoing litigation. Liraglutide (Saxenda) patents expire in 2026-2027, potentially allowing generic entry soon after. Semaglutide formulations are protected by patents extending to 2031-2032, though some patent challenges are pending. Tirzepatide patents run through the mid-2030s. The complex manufacturing process for peptide-based GLP-1 medications creates additional barriers to generic competition beyond just patent expiration. Biosimilar versions (similar to generics for biologics) may enter the market first. Even when patents expire, the technical challenges of producing consistent, high-quality peptide medications at scale may delay affordable generic options for several years beyond patent expiration.